T-bet expression in breast cancer predicts survival
Author Information
Author(s): Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Martin F, Fumoleau P, Coudert B, Ghiringhelli F
Primary Institution: Georges François Leclerc Center, Dijon, France
Hypothesis
The presence of T-bet+ T cells in tumor immune infiltrates after neoadjuvant chemotherapy predicts patient survival.
Conclusion
The presence of T-bet+ lymphocytes after neoadjuvant trastuzumab–taxane chemotherapy is associated with better relapse-free survival in HER2-overexpressing breast carcinoma.
Supporting Evidence
- Patients treated with trastuzumab–taxane had significantly more T-bet+ lymphocytes after chemotherapy.
- The presence of T-bet+ lymphocytes was independently associated with improved relapse-free survival.
- Pathological complete response was more frequently achieved in the trastuzumab–taxane group.
Takeaway
This study found that having certain immune cells in breast cancer after treatment can help doctors know if a patient will do better or worse.
Methodology
The study analyzed T-bet+ lymphocyte presence in tumor samples from 102 HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy, using immunohistochemistry and statistical analyses.
Potential Biases
Differences in prognostic variables between treatment groups could affect results.
Limitations
The study's retrospective design may introduce selection bias in the control group.
Participant Demographics
Patients were HER2-overexpressing breast cancer patients, with a median follow-up of 40 months.
Statistical Information
P-Value
P=0.0008 for T-bet+ lymphocyte presence after chemotherapy.
Confidence Interval
95% CI: 1.07–20
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website